ED1 Debate: Are There Long-Term Risks in Pediatric Growth Hormone Treatment?

Program: Endocrine Debates
Clinical Session
Saturday, April 2, 2016: 2:15 PM-3:00 PM
BR East (BCEC)
Alan D Rogol, MD, PhD, University of Virginia, Charlottesville, VA

ADR: Consultant, NovoNordisk, Consultant, Ammonett Pharma, LLC, Consultant, Acerus Pharma, Consultant, Versartis, Consultant, SOV Therapeutics.
2:15 PM

Jean-Claude Carel, MD, Pediatric Endocrinology-Diabetology, Robert Debré Hospital, University Paris Diderot, Paris, France
JCC: Principal Investigator, Lilly USA, LLC, Principal Investigator, Ipsen, Speaker, Novo Nordisk.
2:35 PM

Ron G Rosenfeld, MD, Stat 5 LLC, Los Altos, CA
RGR: Advisory Group Member, Novo Nordisk, Advisory Group Member, Sandoz, Advisory Group Member, OPKO, Ascendis Versartus.
See more of: Endocrine Debates


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire